En développement
Santé·5 g önceRésumé IA
UK Startup to Trial Cancer Drug to Prevent Life-Threatening Side-Effect
Poolbeg Pharma will trial its oral drug POLB 001 at six NHS hospitals to prevent cytokine release syndrome (CRS), a dangerous side-effect of cancer immunotherapy. The drug could improve patient safety and save healthcare systems millions by allowing treatment outside specialist centers.
G
Guardian UK